Quantum Genomics Announces Publication of a New Scientific Article Featuring QGC606

Rhea-AI Summary

Quantum Genomics has published a new article in the Canadian Journal of Cardiology detailing the efficacy of its drug candidate, QGC606, for treating heart failure following myocardial infarction. The study, conducted with INSERM, shows that QGC606 improves cardiac function at a dose six times lower than firibastat and is comparable to ramipril without affecting blood pressure. This positions QGC606 as a potential best-in-class product, reinforcing the company's innovative approach in treating resistant hypertension and heart failure.

Positive

• QGC606 demonstrates significant improvement in cardiac function and reduction of fibrosis post-myocardial infarction.
• Efficacy of QGC606 is comparable to ramipril, a leading heart failure drug, but does not affect blood pressure.
• The research strengthens Quantum Genomics' position in developing best-in-class treatments targeting cardiovascular diseases.

Negative

• None.

PARIS, March 31, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a biopharmaceutical company specializing in the development of a new drug class directly targeting the brain to treat resistant/hard-to-treat hypertension and heart failure, announced the publication of a new scientific article reporting the efficacy of its second drug-candidate, QGC606, in an experimental model of heart failure in the Canadian Journal of Cardiology.

This article, entitled “QGC606, a best-in-class orally active centrally acting aminopeptidase A inhibitor prodrug, for treating heart failure following myocardial infarction,” presents the results of a study conducted with QGC606 in mice following myocardial infarction, in collaboration with the INSERM team led by Catherine Llorens-Cortes at the Collège de France and the team at the Institut of Biology of Paris-Sorbonne University directed by Pr. Onnik Agbulut. The article is available online on the journal’s website (Articles in Press: Canadian Journal of Cardiology (onlinecjc.ca); DOI: 10.1016/j.cjca.2022.01.019).

The data reported in this article demonstrate the effectiveness of oral treatment with QGC606 to improve cardiac function and reduce fibrosis, thus preventing the onset of heart failure after myocardial infarction, at a dose 6 times lower than the firibastat. Data shows the efficacy of QGC606 is also comparable to that of ramipril selected as a drug reference but unlike ramipril, QGC606, like firibastat, does not affect blood pressure levels in mice.

« The experimental data obtained with this new product are particularly promising because they position QGC606 as a potential best-in-class product », said Fabrice Balavoine, Vice-President Research & Development at Quantum Genomics. « This represents a reinforcement of the results already obtained with firibastat and further validate the therapeutic benefit of brain aminopeptidase A inhibitors in preventing cardiac dysfunction after myocardial infarction. »

About Quantum Genomics

Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular drugs, based on the Brain Aminopeptidase A Inhibition (BAPAI) mechanism. It is the only company in the world to pursue this innovative approach directly targeting the brain, founded upon more than twenty years of research work by Paris-Descartes University and the INSERM/CNRS laboratory led by Dr. Catherine Llorens-Cortès at the Collège de France. Quantum Genomics thus aims to develop innovative treatments for complicated or even resistant hypertension (in approximately 30% of patients it is poorly controlled, or treatment failure occurs), and heart failure (one in two patients diagnosed dies within five years).

Based in Paris, the company is listed on the Euronext Growth market in Paris (FR0011648971 - ALQGC) and is registered on the US OTCQX market (symbol: QNNTF).
Find out more at www.quantum-genomics.com, or on our Twitter and Linkedin accounts.

Contacts

Quantum Genomics
contact@quantum-genomics.fr
Edifice Communication (EUROPE)
Financial and media communication quantum-genomics@edifice-communication.com
LifeSci (USA)
Mike Tattory Media communication +1 (646) 751-4362 - mtattory@lifescipublicrelations.com

FAQ

What are the key findings of Quantum Genomics' recent publication on QGC606?

The publication shows that QGC606 significantly improves cardiac function and reduces fibrosis in heart failure models, at a much lower dose compared to firibastat.

How does QGC606 compare to other heart failure treatments?

QGC606 is comparable to ramipril in terms of efficacy but uniquely does not affect blood pressure, positioning it as a promising alternative.

Where can I find the published study on QGC606?

The study is published in the Canadian Journal of Cardiology and is available online at the journal's website.

What is the significance of Quantum Genomics' research on heart failure?

It reinforces the potential of QGC606 as a best-in-class treatment, enhancing the company’s portfolio targeting resistant hypertension and heart failure.

What is the stock symbol for Quantum Genomics?

The stock symbol for Quantum Genomics is QNNTF, listed on the OTCQX market.